A Study Evaluating How Moderate Liver Impairment Affects the Absorption, Distribution, Metabolism, and Elimination of Sevabertinib After a Single Oral Dose

NCT07102095 | Completed Phase 1 FDA Drug

• 1 other identifier: 22988
• Study Type: interventional
• Target: 18
• Locations: 1 country
• Sites: 2

Brief Summary

This is a research study to understand how liver impairment affects the way the body processes a new cancer medicine called sevabertinib (BAY 2927088). Sevabertinib is an experimental drug being developed to treat certain types of cancers that have specific genetic changes called HER2 mutations. This includes lung cancer, tumors that have spread to other parts of the body (metastatic), and tumors that cannot be removed with surgery (unresectable). Before this medicine can be given to cancer patients with liver problems, researchers need to understand how liver disease might change the way the body handles the drug. The study will include about 20 people divided into two groups: 10 people with moderate liver problems (called Child-Pugh B liver impairment) and 10 healthy people with normal liver function. The healthy volunteers will be matched to the liver patients by age, sex, and weight to make fair comparisons. All participants will take a single 20 mg dose of sevabertinib by mouth and stay in the research clinic for 5 days. During this time, researchers will take blood samples at specific times to measure how much drug is in the blood and how long it stays in the body. They will also monitor participants closely for any side effects. The main goal is to see if people with liver problems have different drug levels in their blood compared to healthy people. This information will help doctors determine if cancer patients with liver disease need different doses of sevabertinib to be safe and effective. The study will also look at the safety and tolerability of sevabertinib in both groups. Participants will have follow-up visits to ensure their continued health and safety. This research is important because many cancer patients also have liver problems, and understanding how liver disease affects this new cancer treatment will help ensure it can be used safely and effectively in all patients who might benefit from it.

Conditions

Hepatic Insufficiency; Liver Diseases; Pharmacokinetics; Drug Metabolism

Outcome Measures

Primary Outcomes (4)

• Area under plasma concentration-time curve (AUC) of sevabertinib

  To assess the influence of hepatic impairment on sevabertinib exposure. AUC from time zero to the last data point larger than the lower limit of quantification (LLOQ) (AUC(0-tlast) and the unbound AUC(0-tlast) will be used as the main parameters if AUC cannot be reliably determined in all participants.

  0-96 hours post-dose

• Unbound area under plasma concentration-time curve AUC (AUCu) of sevabertinib

  To assess the influence of hepatic impairment on sevabertinib exposure. AUC from time zero to the last data point larger than the lower limit of quantification (LLOQ) (AUC(0-tlast) and the unbound AUC(0-tlast) will be used as the main parameters if AUC cannot be reliably determined in all participants.

  0-96 hours post-dose

• Maximum observed drug concentration (Cmax) of sevabertinib in plasma

  To assess the influence of hepatic impairment on sevabertinib exposure.

  0-96 hours post-dose

• Unbound Cmax (Cmax,u) of sevabertinib in plasma

  To assess the influence of hepatic impairment on sevabertinib exposure.

  0-96 hours post-dose

Secondary Outcomes (1)

• Incidence and severity of adverse events

  From signing of informed consent form (ICF) until follow-up visit (approximately 2 weeks).

Study Arms (2)

Arm A: Moderate Hepatic Impairment

EXPERIMENTAL

Approximately 10 participants with moderate impaired hepatic function (Child-Pugh B) to achieve approximately 8 evaluable participants

Drug: Sevabertinib

Arm B: Normal Hepatic Function

EXPERIMENTAL

Approximately 10 matched control participants for Arm A with normal hepatic function

Drug: Sevabertinib

Interventions

Sevabertinib DRUG

Single oral dose of 20 mg sevabertinib administered as 2 x 10 mg film-coated tablets

Arm A: Moderate Hepatic Impairment; Arm B: Normal Hepatic Function

Eligibility Criteria

• Age: 18 Years - 79 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Participant must be 18 to 79 years of age inclusive, at the time of signing the informed consent.
• Normal hepatic function or moderate hepatic impairment.
• Body weight of at least 50 kg and BMI of within the range 18 to 40 kg/m2 inclusive.
• Female, of non childbearing potential only. Females must not be pregnant or breastfeeding, and must be documented as of non-childbearing potential (WONCBP). A negative pregnancy test is required.
• Male study participants of reproductive potential must agree to use adequate contraception when sexually active from signing the Informed Consent Form (ICF) until at least 3 months after the last dose of study intervention, and refrain from sperm donation during study intervention and for 3 months after the last dose of study intervention.
• Signed ICF.
• Documented liver disease with findings consistent with cirrhosis confirmed by histopathology, laparoscopy, fibroscan, CT, MRI, or ultrasound, AND
• Hepatic impairment (Child-Pugh B), AND
• Stable liver disease (i.e., same Child-Pugh class for at least 2 months prior to screening).
• Have normal hepatic function, AND
• Fulfil Arm A matching criteria (sex, age, and body weight).

You may not qualify if:

• Any existing relevant uncontrolled diseases of vital organs (e.g., heart, GI, pulmonary, or renal diseases), central nervous system (e.g., seizures), or other organs (e.g., uncontrolled diabetes mellitus \[other than those related to hepatic impairment for the hepatically-impaired participants\]) within 4 weeks prior to study intervention administration, including medically relevant infections and acute GI conditions (vomiting, diarrhea, and/or constipation).
• Known clinically relevant GI tract disorders (e.g., stomach ulcers, duodenal ulcers, GI bleeding, acute gastritis) or inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis).
• Malignancy diagnosed or treated within the past 5 years (hepatocellular carcinoma within the past 2 years). Note: This does not include adequately-treated basal cell carcinoma or localized squamous cell carcinoma of the skin.
• Participants with primary or secondary biliary cirrhosis, or with sclerosing cholangitis.
• Pre-existing diseases for which it can be assumed that the absorption, distribution, metabolism, elimination, and effects of the study intervention will be affected.
• Renal impairment with an eGFR ≤40 mL/min according to the CKD-EPI equation.
• Use of strong or moderate CYP3A4 inducers or inhibitors within 4 weeks or 5 half-lives prior to study intervention administration (whichever is longer) until last day of blood sampling for PK after study intervention administration.
• Use of drugs which may affect absorption, unless the drug is part of the mandatory dosing regimen for treatment of hepatic impairment or related conditions.
• Use of supplements or herbal remedies within 2 weeks prior to the first study intervention administration (except for vitamin supplementation).
• Use of anti-coagulant drugs.
• Positive alcohol blood/urine test at screening.
• Positive blood/urine drug screening indicating drug abuse (except for participants with hepatic insufficiency on an approved prescription for opioids or benzodiazepines who agree to withhold the use of opioids or benzodiazepines from 12 hours pre- and 12 hours post-intervention administration).
• Insufficiently controlled diabetes mellitus with HbA1c \>10% within 6 months prior to study intervention administration.
• Consumption of food and beverages containing grapefruit, Seville orange, tangelo, or pomelos within 2 weeks prior to study intervention administration and up to the last PK sampling.
• Special diets preventing the participants from eating the standard meals during the study or unwillingness to eat the standard meals during the study.

Sponsors & Collaborators

• Bayer: lead

Study Sites (2)

Clinical Pharmacology of Miami - Oncology

Miami, Florida, 33014, United States

Location

Orlando Clinical Research Center

Orlando, Florida, 32809, United States

Location

MeSH Terms

Conditions

Hepatic Insufficiency; Liver Diseases

Condition Hierarchy (Ancestors)

Digestive System Diseases

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: BASIC SCIENCE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR
• Expanded Access: Yes

Study Record Dates

• First Submitted: July 18, 2025
• First Posted: August 3, 2025
• Study Start: July 24, 2025
• Primary Completion: December 3, 2025
• Study Completion: December 3, 2025
• Last Updated: February 10, 2026

Record last verified: 2026-02

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)